Table 4

Secondary end point as determined by MRI evaluation for the intention-to-treat population*

AnalysisIRR (95% CI)P value
Number of T1-enhancing lesions (month 30)0.29 (0.11 to 0.76)0.011
New/enlarging T2-hyperintense lesions at month 30 versus baseline0.49 (0.38 to 0.62)<0.0001
  • *All analyses adjusted for: age, sex, years of diagnosis, baseline Expanded Disability Status Scale, relapses during normalisation.

  • IRR, Incidence rate ratio.